Litcius/Paper detail

Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns

Elisabeth Mahase

2021BMJ50 citationsDOI

Topics & Concepts

Agency (philosophy)DrugMedicineBusinessPharmacologyPhilosophyEpistemologyScience, Research, and MedicineHealth Systems, Economic Evaluations, Quality of Life
Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns | Litcius